• Helus Pharma (HELP) announced a US$50 million underwritten public offering of 10,309,280 common shares priced at $4.85 per share on June 24, 2026.
  • The offering is expected to close on June 25, 2026, and the net proceeds will be used to fund the company's HLP003, HLP004, and HLP005 programs, as well as general corporate purposes.
  • The stock is trading 5.7% higher at $5.38 in pre-market, extending a multi-day momentum rally, despite the dilution implied by the offering, suggesting market confidence in the funding for its pipeline development.